Type 2 DiabetesNCT06814171
UBC Breakfast Study 2.0
A study testing Low-carbohydrate breakfast in people with Type 2 Diabetes, run by University of British Columbia at 1 site in Canada.
Trial summary
Type 2 diabetes (T2D), a prevalent metabolic disorder impacting >3 million Canadians, is characterized by insulin resistance and high blood glucose. Chronically elevated blood glucose (i.e., hyperglycemia) and swings in glucose (i.e., glucose variability) contribute to complications of T2D. Read more about this study
- Who is it for?
- Ages 30 to 79 years
- Conditions the study is for
- Type 2 Diabetes
- What is being tested?
- Low-carbohydrate breakfast
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 280 participants
- Where
- 1 siteCanada
- Study dates
- 1 Apr 2025to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 79 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- physician-diagnosed T2D, ii) 30-79 years old and iii) on stable medication for at least 3 months
Who cannot join
- Use of exogenous insulin; ii) taking more than 3 glucose lowering medications; iii) ongoing medical treatment for diseases such as cancer, auto-immune or inflammatory disease, or kidney disorders; iv) allergy, intolerance or aversion to eggs or any other dietary restrictions (e.g., vegan, breakfast skipping) that will prevent them from following the standardized study diets; v) being unable to follow the controlled diet instructions; vi) currently following a low-carbohydrate or very low-carbohydrate diet (ketogenic diet); vii) currently pregnant or lactating, or planning on becoming pregnant within the next 12 months; viii) with scheduled surgery or medical intervention that prevents following study diet; and ix) being unable to follow remote guidance by internet or smartphone.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
University of British Columbia - Okanagan
Kelowna, British Columbia, V1V1V7
About this study
Official title: Long-term Impact of a Low-carbohydrate Versus Low-fat Breakfast on Blood Glucose Control in Type 2 Diabetes
Type 2 diabetes (T2D), a prevalent metabolic disorder impacting >3 million Canadians, is characterized by insulin resistance and high blood glucose. Chronically elevated blood glucose (i.e., hyperglycemia) and swings in glucose (i.e., glucose variability) contribute to complications of T2D. Specifically, post-meal hyperglycemic spikes are independent risk factors for cardiovascular disease and mortality. People with T2D often exhibit a different circadian pattern from healthy individuals, with higher glucose excursions in the morning, after breakfast. This makes breakfast a crucial meal in achieving glycemic control. One strategy to reduce or eliminate this high glucose excursion is to consume a low-carbohydrate breakfast. Our recently published 3-month clinical trial (Oliveira et al., AJCN 2023) - funded by the Egg Farmers of Canada (EFC) \& Egg Nutrition Center (ENC) - highlighted the positive impact of a simple dietary intervention, where individuals were advised to consume an egg-based, low-carbohydrate breakfast. This intervention led to improved glycemic control assessed by continuous glucose monitoring and reduced overall energy and carbohydrate intake when compared to a low-fat guideline breakfast. While we saw a within-group reduction HbA1c in the egg-based low-carbohydrate breakfast group, the between group difference did not reach statistical significance. Since HbA1c reflects the average glucose over the preceding 3 months, likely, our previous study's duration was not long enough to demonstrate significant reductions in HbA1c. For a low-carbohydrate breakfast to be recognized as an evidence-based strategy in nutrition and clinical practice guidelines, a longer-term study that demonstrates reductions in HbA1c is needed.
Collectively, our promising early results demonstrate that the time is right and that our team is poised to deliver a longer, well-powered randomized controlled trial (RCT) to solidify low-carbohydrate breakfasts as an evidence-based strategy to improve glucose control and improve health outcomes for people living with T2D.
Read the detailed description
Research Question: Does the advice and guidance to consume a long-term low-carbohydrate breakfast impact blood glucose levels in people with type 2 diabetes?
Objectives
The specific aims are to conduct a RCT to determine if advice and guidance to consume a low-carbohydrate breakfast, compared to standard guidelines control breakfast, for one year:
Improves glycemic control assessed by HbA1c (primary outcome) in individuals with type 2 diabetes (T2D); Improves glycemic variability and lowers postprandial hyperglycemia in individuals with T2D; Reduces body weight and fat mass in individuals with T2D; Reduces feelings of hunger and consequently lowers daily energy and carbohydrate intake in individuals with T2D.
Hypothesis:
Advice and guidance to consume a low-carb high-fat breakfast, compared to a standard control low-fat breakfast over 1 year will reduce HbA1c levels; When compared to a low-fat breakfast, low-carb high-fat breakfast will improve glucose monitoring metrics.
Compared to a low-fat breakfast, a low-carb high-fat breakfast will lower feelings of self-reported hunger; A low-carb high-fat breakfast will improve body composition in individuals with T2D.
Background Information
In the years leading up the pandemic (2016 to 2019), almost 1 in 10 Canadian adults aged 20 to 79 (9%) had diabetes. The prevalence of diabetes ranged from 1% of Canadians aged 20 to 39 to almost one in five seniors aged 60 to 79 (18%) (Statistics Canada). The high prevalence is associated with a high personal, clinical and economic burden, with diabetes resulting in approximately 15,700 deaths each year in Canada (Cho et al., 2018). Clearly, strategies to improve glucose control and reduce the burden of T2D are attractive from a quality of life and economic standpoint.
Lowering dietary carbohydrate intake has been shown to improve blood glucose control and is now recognized as an evidence-based nutritional strategy in T2D (Churuangsuk et al., 2020). However, low-carbohydrate diets are often criticized as being too difficult to sustain in the long-term. One potential strategy is to limit carbohydrate intake at only one daily meal. Since the largest hyperglycemic spike usually occurs in the morning after the first meal, manipulating the carbohydrate content of the breakfast may be a simple strategy to improve glycemic control in people with T2D.[ Long-term trials specifically examining low-carbohydrate egg-based breakfasts are lacking. To our knowledge, our last RCT (Oliveira et al., AJCN 2023) is the most recent and robust evidence examining the effects of a low-carbohydrate breakfast on glucose control in T2D up to now (described in detail below). Pedersen et al. (2016) demonstrated in T2D patients that excluding carbohydrates from the first meal of the day could mitigate the significant glucose spike typically observed after breakfast. Similarly, Park et al. (2014) found that a high-protein breakfast reduced postprandial glucose concentrations without exacerbating the glucose response to subsequent meals, suggesting that incorporating more protein into breakfast could be a therapeutic approach for T2D management.
Considering our publications demonstrating enhanced glycemic control in T2D patients following a low-carbohydrate breakfast (Chang et al., 2019 and Oliveira et al., AJCN 2023), alongside existing research indicating the health benefits of "bigger" and high-protein breakfasts in T2D, there is compelling justification for conducting a longer-term, well-designed, adequately powered randomized controlled trial (RCT). We hypothesize that consuming a low-carbohydrate breakfast for 1-year will improve blood glucose control and be recognized as a scientifically substantiated, evidence-based nutritional strategy for T2D, with promise for potential incorporation into clinical practice guidelines.
Research Method
Overview
Two-hundred eighty (N=280) individuals with diagnosed T2D (30-79 years old), will be recruited from across Canada for a 1-year parallel-group remotely-delivered RCT through online and newspaper advertising, emails, third-part recruitment agency as well as word of mouth. Participants will be randomized to consume a low-carbohydrate breakfast (LC, n=140) or a low-fat "standard care" control breakfast (CTL, n=140) for 12 months, stratified by age (30-50, 51-79) and biological sex (M/F).
Participants will continue to take any medications as instructed by their physicians throughout this real-world trial but will be asked to report any changes that occur to study personnel over the 1-year period.
Experimental conditions
A 1-year parallel-group RCT is proposed. Due to the nature of the dietary intervention trial, study participants and investigators will not be blinded - however, masking will be implemented wherever possible (e.g., for data analysis). Eligible participants will be randomized to either the:
- Low Carbohydrate Breakfast (LC, n=140) or ii) Low-fat "standard care" Control Breakfast (CTL, n=140) Both breakfasts will be consumed daily for a period of 1-year.
Breakfast options Similar to our previous trial, each group will be provided with an initial menu of 12 recipes consisting of ~400-500 kcal from which to choose each morning. LC breakfasts will contain <10% carbohydrates, 60-75% fat, and 15-30% protein (e.g., omelette with cheese) and CTL breakfasts will contain 45-70% carbohydrates, 20-40% fat, 15-25% protein (e.g., oatmeal with berries). Participants will be instructed to have their first meal of the day (before 12pm) as per recipes and to upload a daily photo of their breakfast to confirm compliance. As in our previous low-carbohydrate breakfast study no instructions will be provided for other meals as the goal is to be free-living with minimal intervention and increased potential for implementation and translation to real-world life.
Dietary intake assessment Participants will be guided to register three 3-day food records (2 weekdays and 1 weekend day) at baseline, 3, 6, 9 and 12 months of the trial through REDCap-UBC links. Macronutrient composition and total caloric intake will be calculated using ESHA software to determine any group differences across time.
Hunger and Fullness questionnaire Participants will complete a 100 mm Visual Analog Scales (VAS) to measure self-reported hunger, fullness and desire for sweet and savoury foods at multiple timepoints across one day at baseline, 3, 6, 9 and 12 months. They will be advised to fill out the survey after breakfast.
GODIN Leisure-Time Exercise Questionnaire Participants will be asked to report changes to their physical activity by completing a GODIN questionnaire through a REDCap-UBC link sent by email at baseline and end of the trial. The Godin Leisure-Time Exercise Questionnaire allows the assessment of self---reported leisure---time physical activity.
Chronotype survey (exploratory outcome) Chronotype will be determined using the Morningness-Eveningness questionnaire (MEQ) send through a REDCap-UBC link by email at baseline.
Blood testing Blood samples will be collected at baseline and after 12 months for HbA1c and lipids (triglycerides, total, HDL, and LDL cholesterol) at the nearest local laboratory with lab requisition provided by research team.
Anthropometry Anthropometric measures (height, body weight, and waist circumference) will be assessed at baseline, 3, 6, 9 and, 12 months during Zoom calls with the dietitian.
Glucose monitoring Participants in both groups will receive a flash glucose monitoring sensor (FreeStyle Libre 2) at baseline, to record their glucose levels for 14 days before starting the breakfast recipes. Once intervention has started, they will wear the flash glucose monitoring sensor for 14 days at 6 and 12 months to capture changes related to dietary approach. The sensor will be an informative tool for glycemic control in both groups by measuring daily postprandial hyperglycemia and providing the data necessary to calculate 24-hour average, post-meal incremental areas under the curve (iAUC), and glycemic variability.
- Conditions
- Type 2 Diabetes
- Being tested
- Low-carbohydrate breakfast, Low-fat Control breakfast
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low-carbohydrate breakfastOther
Daily low-carbohydrate breakfasts for one year.
Low-fat Control breakfastOther
Low-fat breakfasts for one year.
| Study group | Role | What they receive |
|---|---|---|
| Low-carbohydrate breakfast | Experimental | Not described Receives: Other: Low-carbohydrate breakfast |
| Low-fat Control breakfast | Active comparator | Not described Receives: Other: Low-fat Control breakfast |
What is being measured
The primary outcome is the main question the study is designed to answer.
HbA1c
Blood HbA1c
Measured: At baseline and after 12 months
Secondary outcomes (13)
24 h average glucose by continuous glucose monitoring
Continuous glucose monitoring for 14 days to assess 24hour average glucose
Measured: Baseline, 6 and 12 months
Post-meal areas under the curve [AUC] glucose by continuous glucose monitoring
14 day continuous glucose monitoring to assess Post-meal areas under the curve [AUC] glucose
Measured: Baseline, 6 and 12 months
Glycemic variability by continuous glucose monitoring
14-day continuous glucose monitoring to assess glycemic variability
Measured: Baseline, 6 and 12 months
Body weight
Self-reported body weight in kg
Measured: Baseline, 3, 6, 9 and, 12 months
Body mass index
Calculated body mass index (BMI) as kg/m2.
Measured: Baseline, 3, 6, 9 and, 12 months
Waist circumference
Self-measured and self reported waist circumference in inches
Measured: Baseline, 3, 6, 9 and, 12 months
Triglycerides
Blood triglycerides
Measured: Baseline and 12 months
Total cholesterol
Blood total cholesterol
Measured: Baseline and 12 months
HDL cholesterol
Blood HDL cholesterol
Measured: Baseline and 12 months
LDL cholesterol
Blood LDL cholesterol
Measured: Baseline and 12 months
Energy intake
Daily energy intake (kcal) measured by 3-day food records
Measured: Baseline, 3, 6, 9, and 12 months
Carbohydrate intake
Daily carbohydrate intake (g) and (kcal) measured by 3-day food records
Measured: Baseline, 3, 6, 9, and 12 months
HbA1c at 6 months
HbA1c at 6 month
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Feb 2025
- Study start1 Apr 2025
- Primary completion30 Jun 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- More trials run by University of British ColumbiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 280 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of British Columbia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jonathan Little, University of British Columbia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06814171
- Sponsor's protocol ID
- H25-00043
- Status last verified
- Jun 2025
- First submitted
- 3 Feb 2025
- Last updated
- 10 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Compiled data will be provided upon reasonable request.
Publications
Oliveira BF, Chang CR, Oetsch K, Falkenhain K, Crampton K, Stork M, Hoonjan M, Elliott T, Francois ME, Little JP. Impact of a Low-Carbohydrate Compared with Low-Fat Breakfast on Blood Glucose Control in Type 2 Diabetes: A Randomized Trial. Am J Clin Nutr. 2023 Jul;118(1):209-217. doi: 10.1016/j.ajcnut.2023.04.032. Epub 2023 May 29.
PubMed 37257563
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-term Impact of a Low-carbohydrate Versus Low-fat Breakfast on Blood Glucose Control in Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT06814171
- Acronym / sponsor ID
- H25-00043
- Conditions
- Type 2 Diabetes
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 280 participants (estimated)
- Lead sponsor
- University of British ColumbiaUniversity, hospital or other
- Study start
- 1 Apr 2025 (actual)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 7 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Type 2 diabetes (T2D), a prevalent metabolic disorder impacting >3 million Canadians, is characterized by insulin resistance and high blood glucose. Chronically elevated blood glucose (i.e., hyperglycemia) and swings in glucose (i.e., glucose variability) contribute to complications of T2D. Specifically, post-meal hyperglycemic spikes are independent risk factors for cardiovascular disease and mortality. People with T2D often exhibit a different circadian pattern from healthy individuals, with higher glucose excursions in the morning, after breakfast. This makes breakfast a crucial meal in achieving glycemic control. One strategy to reduce or eliminate this high glucose excursion is to consume a low-carbohydrate breakfast. Our recently published 3-month clinical trial (Oliveira et al., AJCN 2023) - funded by the Egg Farmers of Canada (EFC) \& Egg Nutrition Center (ENC) - highlighted the positive impact of a simple dietary intervention, where individuals were advised to consume an egg-based, low-carbohydrate breakfast. This intervention led to improved glycemic control assessed by continuous glucose monitoring and reduced overall energy and carbohydrate intake when compared to a low-fat guideline breakfast. While we saw a within-group reduction HbA1c in the egg-based low-carbohydrate breakfast group, the between group difference did not reach statistical significance. Since HbA1c reflects the average glucose over the preceding 3 months, likely, our previous study's duration was not long enough to demonstrate significant reductions in HbA1c. For a low-carbohydrate breakfast to be recognized as an evidence-based strategy in nutrition and clinical practice guidelines, a longer-term study that demonstrates reductions in HbA1c is needed.
Collectively, our promising early results demonstrate that the time is right and that our team is poised to deliver a longer, well-powered randomized controlled trial (RCT) to solidify low-carbohydrate breakfasts as an evidence-based strategy to improve glucose control and improve health outcomes for people living with T2D.
Detailed description
Research Question: Does the advice and guidance to consume a long-term low-carbohydrate breakfast impact blood glucose levels in people with type 2 diabetes?
Objectives
The specific aims are to conduct a RCT to determine if advice and guidance to consume a low-carbohydrate breakfast, compared to standard guidelines control breakfast, for one year:
Improves glycemic control assessed by HbA1c (primary outcome) in individuals with type 2 diabetes (T2D); Improves glycemic variability and lowers postprandial hyperglycemia in individuals with T2D; Reduces body weight and fat mass in individuals with T2D; Reduces feelings of hunger and consequently lowers daily energy and carbohydrate intake in individuals with T2D.
Hypothesis:
Advice and guidance to consume a low-carb high-fat breakfast, compared to a standard control low-fat breakfast over 1 year will reduce HbA1c levels; When compared to a low-fat breakfast, low-carb high-fat breakfast will improve glucose monitoring metrics.
Compared to a low-fat breakfast, a low-carb high-fat breakfast will lower feelings of self-reported hunger; A low-carb high-fat breakfast will improve body composition in individuals with T2D.
Background Information
In the years leading up the pandemic (2016 to 2019), almost 1 in 10 Canadian adults aged 20 to 79 (9%) had diabetes. The prevalence of diabetes ranged from 1% of Canadians aged 20 to 39 to almost one in five seniors aged 60 to 79 (18%) (Statistics Canada). The high prevalence is associated with a high personal, clinical and economic burden, with diabetes resulting in approximately 15,700 deaths each year in Canada (Cho et al., 2018). Clearly, strategies to improve glucose control and reduce the burden of T2D are attractive from a quality of life and economic standpoint.
Lowering dietary carbohydrate intake has been shown to improve blood glucose control and is now recognized as an evidence-based nutritional strategy in T2D (Churuangsuk et al., 2020). However, low-carbohydrate diets are often criticized as being too difficult to sustain in the long-term. One potential strategy is to limit carbohydrate intake at only one daily meal. Since the largest hyperglycemic spike usually occurs in the morning after the first meal, manipulating the carbohydrate content of the breakfast may be a simple strategy to improve glycemic control in people with T2D.[ Long-term trials specifically examining low-carbohydrate egg-based breakfasts are lacking. To our knowledge, our last RCT (Oliveira et al., AJCN 2023) is the most recent and robust evidence examining the effects of a low-carbohydrate breakfast on glucose control in T2D up to now (described in detail below). Pedersen et al. (2016) demonstrated in T2D patients that excluding carbohydrates from the first meal of the day could mitigate the significant glucose spike typically observed after breakfast. Similarly, Park et al. (2014) found that a high-protein breakfast reduced postprandial glucose concentrations without exacerbating the glucose response to subsequent meals, suggesting that incorporating more protein into breakfast could be a therapeutic approach for T2D management.
Considering our publications demonstrating enhanced glycemic control in T2D patients following a low-carbohydrate breakfast (Chang et al., 2019 and Oliveira et al., AJCN 2023), alongside existing research indicating the health benefits of "bigger" and high-protein breakfasts in T2D, there is compelling justification for conducting a longer-term, well-designed, adequately powered randomized controlled trial (RCT). We hypothesize that consuming a low-carbohydrate breakfast for 1-year will improve blood glucose control and be recognized as a scientifically substantiated, evidence-based nutritional strategy for T2D, with promise for potential incorporation into clinical practice guidelines.
Research Method
Overview
Two-hundred eighty (N=280) individuals with diagnosed T2D (30-79 years old), will be recruited from across Canada for a 1-year parallel-group remotely-delivered RCT through online and newspaper advertising, emails, third-part recruitment agency as well as word of mouth. Participants will be randomized to consume a low-carbohydrate breakfast (LC, n=140) or a low-fat "standard care" control breakfast (CTL, n=140) for 12 months, stratified by age (30-50, 51-79) and biological sex (M/F).
Participants will continue to take any medications as instructed by their physicians throughout this real-world trial but will be asked to report any changes that occur to study personnel over the 1-year period.
Experimental conditions
A 1-year parallel-group RCT is proposed. Due to the nature of the dietary intervention trial, study participants and investigators will not be blinded - however, masking will be implemented wherever possible (e.g., for data analysis). Eligible participants will be randomized to either the:
- Low Carbohydrate Breakfast (LC, n=140) or ii) Low-fat "standard care" Control Breakfast (CTL, n=140) Both breakfasts will be consumed daily for a period of 1-year.
Breakfast options Similar to our previous trial, each group will be provided with an initial menu of 12 recipes consisting of ~400-500 kcal from which to choose each morning. LC breakfasts will contain <10% carbohydrates, 60-75% fat, and 15-30% protein (e.g., omelette with cheese) and CTL breakfasts will contain 45-70% carbohydrates, 20-40% fat, 15-25% protein (e.g., oatmeal with berries). Participants will be instructed to have their first meal of the day (before 12pm) as per recipes and to upload a daily photo of their breakfast to confirm compliance. As in our previous low-carbohydrate breakfast study no instructions will be provided for other meals as the goal is to be free-living with minimal intervention and increased potential for implementation and translation to real-world life.
Dietary intake assessment Participants will be guided to register three 3-day food records (2 weekdays and 1 weekend day) at baseline, 3, 6, 9 and 12 months of the trial through REDCap-UBC links. Macronutrient composition and total caloric intake will be calculated using ESHA software to determine any group differences across time.
Hunger and Fullness questionnaire Participants will complete a 100 mm Visual Analog Scales (VAS) to measure self-reported hunger, fullness and desire for sweet and savoury foods at multiple timepoints across one day at baseline, 3, 6, 9 and 12 months. They will be advised to fill out the survey after breakfast.
GODIN Leisure-Time Exercise Questionnaire Participants will be asked to report changes to their physical activity by completing a GODIN questionnaire through a REDCap-UBC link sent by email at baseline and end of the trial. The Godin Leisure-Time Exercise Questionnaire allows the assessment of self---reported leisure---time physical activity.
Chronotype survey (exploratory outcome) Chronotype will be determined using the Morningness-Eveningness questionnaire (MEQ) send through a REDCap-UBC link by email at baseline.
Blood testing Blood samples will be collected at baseline and after 12 months for HbA1c and lipids (triglycerides, total, HDL, and LDL cholesterol) at the nearest local laboratory with lab requisition provided by research team.
Anthropometry Anthropometric measures (height, body weight, and waist circumference) will be assessed at baseline, 3, 6, 9 and, 12 months during Zoom calls with the dietitian.
Glucose monitoring Participants in both groups will receive a flash glucose monitoring sensor (FreeStyle Libre 2) at baseline, to record their glucose levels for 14 days before starting the breakfast recipes. Once intervention has started, they will wear the flash glucose monitoring sensor for 14 days at 6 and 12 months to capture changes related to dietary approach. The sensor will be an informative tool for glycemic control in both groups by measuring daily postprandial hyperglycemia and providing the data necessary to calculate 24-hour average, post-meal incremental areas under the curve (iAUC), and glycemic variability.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Low-carbohydrate breakfast | Experimental | Other: Low-carbohydrate breakfast |
| Low-fat Control breakfast | Active comparator | Other: Low-fat Control breakfast |
Who may qualify
- Ages
- 30 to 79 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- physician-diagnosed T2D, ii) 30-79 years old and iii) on stable medication for at least 3 months
Key exclusion criteria (1 listed)
- Use of exogenous insulin; ii) taking more than 3 glucose lowering medications; iii) ongoing medical treatment for diseases such as cancer, auto-immune or inflammatory disease, or kidney disorders; iv) allergy, intolerance or aversion to eggs or any other dietary restrictions (e.g., vegan, breakfast skipping) that will prevent them from following the standardized study diets; v) being unable to follow the controlled diet instructions; vi) currently following a low-carbohydrate or very low-carbohydrate diet (ketogenic diet); vii) currently pregnant or lactating, or planning on becoming pregnant within the next 12 months; viii) with scheduled surgery or medical intervention that prevents following study diet; and ix) being unable to follow remote guidance by internet or smartphone.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low-carbohydrate breakfastDaily low-carbohydrate breakfasts for one year. | Other | Low-carbohydrate breakfast |
| Low-fat Control breakfastLow-fat breakfasts for one year. | Other | Low-fat Control breakfast |
Primary outcome
HbA1c
Time frame: At baseline and after 12 months
Blood HbA1c
13 secondary outcomes
24 h average glucose by continuous glucose monitoring
Time frame: Baseline, 6 and 12 months
Post-meal areas under the curve [AUC] glucose by continuous glucose monitoring
Time frame: Baseline, 6 and 12 months
Glycemic variability by continuous glucose monitoring
Time frame: Baseline, 6 and 12 months
Body weight
Time frame: Baseline, 3, 6, 9 and, 12 months
Body mass index
Time frame: Baseline, 3, 6, 9 and, 12 months
Waist circumference
Time frame: Baseline, 3, 6, 9 and, 12 months
Triglycerides
Time frame: Baseline and 12 months
Total cholesterol
Time frame: Baseline and 12 months
HDL cholesterol
Time frame: Baseline and 12 months
LDL cholesterol
Time frame: Baseline and 12 months
Energy intake
Time frame: Baseline, 3, 6, 9, and 12 months
Carbohydrate intake
Time frame: Baseline, 3, 6, 9, and 12 months
HbA1c at 6 months
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2025.
- Background: PubMed 37257563Oliveira BF, Chang CR, Oetsch K, Falkenhain K, Crampton K, Stork M, Hoonjan M, Elliott T, Francois ME, Little JP. Impact of a Low-Carbohydrate Compared with Low-Fat Breakfast on Blood Glucose Control in Type 2 Diabetes: A Randomized Trial. Am J Clin Nutr. 2023 Jul;118(1):209-217. doi: 10.1016/j.ajcnut.2023.04.032. Epub 2023 May 29.
- Individual participant dataSharing planned: No. Compiled data will be provided upon reasonable request.
Related trials for Type 2 Diabetes
Active, not recruitingPhase 2
Islet Cell Transplant for Type 1 Diabetes
Type 1 Diabetes Mellitus
Active, not recruitingPhase 4
Diabetes in African Youth
type1diabetes
Active, not recruiting
Metabolic and Inflammatory Outcomes of the Ketogenic Diet Comparing Saturated and Unsaturated Fat Sources
PreDiabetes, Diabetes Mellitus, Type 2
RecruitingObservational study
Washed Microbiota Transplantation for Type 1 Diabetes Mellitus
Type 1 Diabetes
Recruiting
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Low-carbohydrate breakfast in people with Type 2 Diabetes, run by University of British Columbia at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Barbara Oliveira, PhD (250 8599900, barbara.oliveira@ubc.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
HbA1c (time frame: At baseline and after 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06814171, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2025; AzTrials last refreshed its copy on 27 Oct 2026.